CYTL1 Inhibitors
CYTL1 inhibitors comprise a distinct chemical class designed to selectively impede the function of Cytokine-like 1 (CYTL1), a protein thought to play a role in cellular processes such as cell migration and inflammation. The inhibition of CYTL1 is achieved through the interaction of these compounds with the specific signaling pathways and molecular interactions that CYTL1 is involved in. The efficacy of CYTL1 inhibitors lies in their ability to specifically target and disrupt the activity of CYTL1 without affecting the broader cellular functions, ensuring a high degree of specificity in their action. This specificity is critical because it reduces the likelihood of off-target effects that can lead to cellular toxicity or unintended biological consequences. The chemical structures of CYTL1 inhibitors are varied, but they share a common functionality in their ability to bind to the active site or a regulatory domain of the CYTL1 protein, thus preventing its normal interaction with other cellular components that are crucial for its functional activity.
In-depth studies of CYTL1 inhibitors have elucidated the precise biochemical pathways that they influence. These inhibitors typically work by either blocking the active site of the CYTL1 protein, thereby hindering its ability to engage in its normal biological processes, or by altering the conformation of CYTL1, which can negatively impact its stability and lead to a reduction in its activity levels. Because of the direct interaction with CYTL1, these inhibitors are highly effective at downregulating the protein's function. The downstream effects of this inhibition include the disruption of CYTL1-mediated signaling pathways which can have various outcomes depending on the cell type and context. The precise molecular design of CYTL1 inhibitors ensures that they achieve a maximal inhibitory effect while maintaining the integrity of other cellular proteins and pathways, thereby providing a targeted approach to investigating the role of CYTL1 in cellular physiology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cell growth and proliferation. CYTL1 is implicated in cell migration and proliferation, therefore, inhibition of mTOR can lead to a reduction in CYTL1-mediated cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that interferes with the MAPK/ERK pathway. CYTL1's role in cell migration could be influenced by ERK activity, as ERK signaling is pivotal in mediating cellular motility, thus PD98059 may indirectly diminish CYTL1's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT pathway, a key signaling route in survival and proliferation. Given CYTL1's association with these cellular functions, its activity could be lessened as a result of PI3K/AKT pathway inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which disrupts inflammatory responses and stress-induced signaling. As CYTL1 has been linked to inflammation, inhibiting p38 MAPK might reduce CYTL1's functional contribution to these processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, which affects cytoskeletal dynamics and cell contraction. Since CYTL1 is involved in cell migration, inhibiting ROCK could attenuate the cell motility that CYTL1 may promote. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which modulates apoptotic and inflammatory signaling. CYTL1's activity might be related to these pathways, so JNK inhibition could decrease CYTL1's influence on cell survival and inflammation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that can block the MAPK/ERK pathway. By dampening this pathway, the cellular activities linked to CYTL1, such as migration and proliferation, could be indirectly inhibited. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, similar to LY294002, and acts to inhibit the PI3K/AKT pathway. This hampers cell survival and growth signals, potentially reducing CYTL1's role in these processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor that impairs signaling involved in cell proliferation, differentiation, and survival. CYTL1, through its involvement in cellular processes, may be affected by the inhibition of Src family kinases. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin inhibits BMP signaling by targeting the kinase activity of BMP type I receptors. As CYTL1 may play a role in cellular differentiation and migration, inhibition of BMP signaling could indirectly limit CYTL1's functional activity. | ||||||